Roggwil, March 7th, 2022 – After a successful test of the first devices delivered by a second contract manufacturer, a framework agreement was concluded for the delivery of 2,000 tinniwell units. The framework agreement has a term of 36 months and the first delivery of 500 units will begin in June 2022.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
T. +41 714500668